Wave Life Sciences (WVE)

• Market cap: $2.06B
• 1 day: 2.43%
• 5 days: 0.45%
• 1 month: -5.26%
• 3 months: 137.85%
• 6 months: 161.82%
• Year to date: 153.00%
• 1 year: 181.46%
• 5 years: -11.35%
• 10 years: -15.56%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Employees: 268

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

106% more capital invested

Capital invested by funds: $472M [Q2] → $974M (+$502M) [Q3]

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

58% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 38

32% more call options, than puts

Call options by funds: $1.49M | Put options by funds: $1.13M

15.56% more ownership

Funds ownership: 77.21% [Q2] → 92.77% (+15.56%) [Q3]

11% more funds holding

Funds holding: 143 [Q2] → 159 (+16) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 11% upside
• Avg. target: $22 60% upside
• High target: $36 166% upside

10 analyst ratings

• positive: 9 90%
• neutral: 1 10%
• negative: 0 0%

Mizuho Salim Syed 35% 1-year accuracy 7 / 20 met price target	63% upside $22	Outperform Maintained	21 Nov 2024
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target	63% upside $22	Buy Reiterated	13 Nov 2024
Truist Securities Joon Lee 47% 1-year accuracy 17 / 36 met price target	166% upside $36	Buy Maintained	12 Nov 2024
B. Riley Securities Madison El-Saadi 67% 1-year accuracy 2 / 3 met price target	63% upside $22	Buy Maintained	4 Nov 2024
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target	11% upside $15	Sector Perform Maintained	21 Oct 2024